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Abstract: The present study aimed to investigate the antiinflammatory effects of 2 herbal extracts (CDS and CDSM) in rats with
experimental adjuvant arthritis (AA). Joint swelling, development of polyarthritis, blood indices, pro/antioxidant activity, and
proinflammatory cytokine IL-17 in blood serum, as well as the liver and paw histopathology and histochemistry, were assessed. Oral
injections of extracts showed an antiinflammatory effect analogous to that of diclofenac (DF), improved blood indices and suppressed
level of IL-17, significantly diminished joint swelling, and histological changes in the joints. Increase in CAT activity and AOA and
reduction in lipid peroxidation was noted. The preparations did not show toxic effects on the liver. The obtained results suggest that the
prophylactic use of CDS and CDSM have a significant effect on slowing AA progression, similar to the effect of DF. Both preparations
could be potential preventive or therapeutic candidates for the treatment of autoimmune processes in combination with other drugs.
Key words: Adjuvant arthritis, herbal extracts, antioxidant activity

1. Introduction
With the aging of the global population, such diseases
as rheumatoid arthritis (RA), osteoarthritis, and other
bone metabolic disorders are increasingly impacting
public health as well as the economy (1,2). Because
current treatments for arthritis are inefficient, produce
substantial side effects, and tend to be expensive, natural
products, which are devoid of such disadvantages, offer
novel treatment opportunities (3). In recent years, there
has been a vast increase in the number of complementary
drugs purported to have joint-protecting and freeradical scavenging properties (4,5). A number of natural
substances that exhibit antiinflammatory activity and
minimal side effects are also being increasingly tested in
experimental models of arthritis (6,7).
The preparation CDS is a compound consisting of
turmeric (Curcuma longa) dry extract (curcumoids
98%), Harpagophytum procumbens (Hp) dry extract
(harpagosides 8%), and milk thistle (Silybum marianum)
dry extract (silymarin 60%). The compound CDSM is a
composition of these extracts plus methylsulfonylmethane
(MSM), which is widely used as a dietary supplement for
its beneficial effects against arthritis, reducing arthritic and
rheumatic pain. It is used to support the function of joints,
* Correspondence: laima.leonaviciene@imcentras.lt
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often in combination with glucosamine and chondroitin
or other compounds like Boswellia serrata extract and
hyaluronic acid (8). Previous studies have demonstrated
that MSM possesses antioxidant and antiinflammatory
properties (9,10), increasing antioxidant enzyme levels
and reducing malondialdehyde (MDA), myeloperoxidase
(MPO), and TNF-α (9). Its administration protects against
the development of type II collagen-induced arthritis in
mice by modifying immune responses (11).
Among the substances in the preparations CDS and
CDSM, curcumin, derived from the root of the plant
Curcuma longa (turmeric), has been one of the most
promising natural active ingredients (12). Biomedical
research on curcumin is ever-increasing because of its
antiinflammatory and antioxidant effects (13,14). It is
used for the treatment of inflammation, rheumatism,
and other chronic and inflammatory diseases (14). The
antiinflammatory activity of curcumin seems to be
comparable to that of steroidal and nonsteroidal drugs such
as indomethacin and phenylbutazone (13). Curcumin has
been shown to suppress the production of cytokines such
as interferon-γ (IFN-γ), interleukins, and TNF-α (15).
Another component, Harpagophytum procumbens
(Hp), commonly known as devil’s claw, is a perennial plant
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that thrives in arid conditions in southern Africa. Hp is
widely recommended as a popular antiinflammatory and
analgesic preparation for musculoskeletal disorders. The
efficacy of Hp in the relief of arthritic symptoms has been
investigated in numerous animal, clinical, and in vitro
studies (16). Hp acts by way of interleukin and leukocyte
migration to the painful and inflamed joint area (17). It
is an effective and well-tolerated serious treatment option
for mild to moderate degenerative rheumatic disorders,
providing improved quality of life (16).
Silymarin in the preparations CDS and CDSM
is an extract from the seeds of the milk thistle plant,
Silybum marianum. There exists a widely held
view that silymarin promotes liver health through
antioxidant, antiinflammatory, antiproliferative, and
immunomodulatory effects (18).
The purpose of the present study was to examine the effect
of CDS and CDSM on clinical and histological scores by using
Freund’s adjuvant-induced arthritis (AA), because there is a
strong correlation between the efficacy of therapeutic agents
in this model and in RA in humans (17). Pro/antioxidant
activity, antiinflammatory, and immunomodulatory effects
of the preparations were investigated and compared with the
effects of diclofenac (DF).
2. Materials and methods
2.1. Materials
Complete Freund’s adjuvant (CFA) was purchased
from Sigma Aldrich (Calbiochem, USA). Acetic acid,
trichloroacetic acid, orthophosphoric acid, thiobarbituric
acid, nitric acid, ascorbic acid, ferrous sulfate, ammonium
molybdate, hydrogen peroxide, 10% neutral buffered
formalin, hematoxylin, eosin, picrofuxin, and toluidine
blue were obtained from Sigma-Aldrich Chemie and
Fluka Chemie GmbH (Germany); ketamidor from Richer
Pharma AG (Wels, Austria); sedaxylan from Eurovet
Animal Health B.V. (Holland); tetrachloroauric acid
(HAuCl4·3H2O) and tannic acid from Carl Roth GmbH
& Co (Germany); sodium citrate from Penta (Czech
Republic). Diclofenac sodium was purchased from CibaGeigy Ltd. (Switzerland).
Herbal preparations with the code names CDS
and CDSM used in this experiment were prepared
at the pharmaceutical company Aksada and kindly
proposed for investigation. Each dose from the CDS
composition consisted of turmeric (Curcuma longa) dry
extract (curcumoids 98%), devil’s claw (Harpagophytum
procumbens) dry extract (harpagosides 8%), and milk
thistle (Silybum marianum) dry extract (silymarin 60%).
Each dose from the CDSM composition consisted of the
abovementioned extracts and MSM (99.9%). Extracts
contained in CDS and CDSM were standardized by the
HPLC method and the quality was based on Certificates

of Analysis, which corresponds to the European
Pharmacopeia requirements.
2.2. Animals
A total of 46 adult male Wistar rats (age, 8–10 weeks;
weight, 175–200 g) were used for the study. The animals
were housed in plastic cages and maintained under
standard laboratory conditions in the vivarium of the
Department of Biomodels, State Research Institute
Centre for Innovative Medicine. They were fed a standard
pellet diet and received water ad libitum. Throughout
the study, the animals were cared for in accordance with
the European Convention Guide for the Care and Use of
Laboratory Animals, and Lithuanian laws. All experiments
on animals were performed with prior approval of the
Lithuanian Laboratory Use Ethics Committee under the
State Food and Veterinary Service (Protocol No. G2-31).
2.3. Adjuvant-induced arthritis, its evaluation, and
treatment
The animals were randomly divided into 5 groups: 4
experimental (10 animals in each) and a healthy rat group
(6 animals). Adjuvant arthritis (AA) was induced in 40 rats
by the subplantar injection of 0.1 mL of complete Freund’s
adjuvant (CFA). The doses of preparations used in the
animals corresponded to the doses used for humans, and
were estimated by the pharmaceutical company Aksada.
The preparations were suspended in 1% starch gel and
injected orally by gastric intubation 5 times a week in 0.5
mL volume per rat following AA-inducing day. The first
group received 39.73 mg/kg CDS per day; the second, 117
mg/kg CDSM per day; the third, 1 mg/kg DF per day; the
fourth group was the control AA group without treatment;
the fifth, healthy rats. The control AA group and healthy
rat group received 0.5 mL of starch gel as vehicle. The
experiment lasted 17 days. The antiarthritic effect of
the preparations was evaluated by measuring the paw
volume plethysmometrically 3 times a week by using a
plethysmometer (PVP1001; Kent Scientific Corporation).
On day 17, the rats were euthanized by decapitation under
ketamidor–sedaxylan anesthesia. Blood, liver, and injected
paws were collected for further investigation. The leukocyte
count (performed by using a hematological analyzer from
Picoscale, Hungary) and erythrocyte sedimentation rate
(ESR) were determined in the blood. Blood samples were
centrifuged at 800 × g for 10 min to obtain serum samples
which were stored frozen at 20 °C until testing.
2.4. Pro/antioxidant activity of blood serum
Lipid peroxidation, assessed as malondialdehyde (MDA)
levels in the blood serum and expressed as nmol/mL, was
determined by thiobarbituric acid reaction at a wavelength
of 532 nm by the method of Gavrilov et al. (19). Catalase
(CAT) activity, expressed in nmol/L per min, was measured
at the wavelength 410 nm as described by Koroliuk et al.
(20). Total antioxidant activity (AOA) was determined
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3. Results
3.1. Clinical and hematological indices
The CDS preparation significantly suppressed joint
swelling until day 13 (P < 0.01–0.001); CDSM significantly
suppressed joint swelling throughout the experiment (P
< 0.02–0.001) (Figure 1). Polyarthritis did not develop in
the treated rats, whereas in the control AA group it was
observed in 30% of the animals.
There was a significant increase in ESR and the leukocyte
count of the arthritic rats when compared with the
healthy-animal group (Figure 2A). The CDS and CDSM
preparations significantly reduced ESR by 60.4% (P <
0.001) and 45.4% (P < 0.01) respectively, and leukocyte
count by 45.6% (P < 0.001) and 44.5% (P < 0.001)
compared with the control AA group.
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in the reaction with thiobarbituric acid, as described by
Galaktionova et al. (21). The precise description of the
methods used has been published previously (22). The
optical density of investigated indices was determined
with a spectrophotometer (Marcell Pro 300; Poland).
2.5. Histology
The liver and injected paws from AA and healthy rats
were excised followed by routine neutral formalin fixation,
decalcification, and paraffin embedding. Paraffin beeswax
tissue blocks were prepared for sectioning at 5-µm thickness
by sledge microtome. The obtained tissue sections were
collected on glass slides, deparaffinized, and stained with
hematoxylin–eosin, picrofuxin, and toluidine blue for
histopathological and histochemical examination with the
light microscope. Histological assessment of changes in the
liver and joint tissues were estimated by using a 4-point score
(0–3), where 0 indicated the absence of changes and 3 was
the most severe expression of a particular symptom. During
the processing and analysis of tissues, the pathologist was
blinded to the animal groups and the treatments.
2.6. Measurement of cytokine IL-17 level
Cytokine IL-17 level was measured in the serum of
the control and experimental animals by enzymelinked immunosorbent assay (ELISA) kit specific for
rats (ab119536-IL-17 Rat ELISA Kit) according to the
procedure recommended by manufacturer’s instructions
(abcam, UK). Each sample was assayed in duplicate. The
concentration of cytokine was determined with the help of
a standard curve.
2.7. Statistical analysis
Statistical analysis was done by one-way analysis of
variance ANOVA using PRISM Software (GraphPad
Software, San Diego, CA, USA) followed by Student’s t-test.
The nonparametric Mann–Whitney U test was used to
evaluate the histological changes. All data were expressed
as the mean ± SEM and considered to be statistically
significant at P values smaller than or equal to 0.05.
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Figure 1. Joint swelling of rats with adjuvant arthritis (AA)
treated with CDS, CDSM, and diclofenac (DF). *The differences
are statistically significant in comparison with the control AA
group.

3.2. Effect of CDS and CDSM on IL-17 level in the blood
serum
The level of cytokine IL-17 in the serum was detected
on day 17 after immunization with CFA (Figure 2B). It
significantly increased in the control AA group compared
with the healthy animals (P < 0.0001). CDS and CDSM
suppressed IL-17 level by 45.4% (P < 0.05) and 30.23%,
respectively.
3.3. Effect of CDS and CDSM on lipid peroxidation and
antioxidant activity
The levels of lipid peroxidation (MDA) were found to be
significantly (P < 0.0001) increased in the control AA rats
compared to the normal (healthy) control group (Figure
3). This was accompanied by a marked (P < 0.001) 43%
and 39.9% decrease in AOA and CAT activity. In contrast,
treatment with CDS (Group 1) and CDSM (Group
2) showed a significant lowering effect on MDA level
(suppression by 50% and 46% respectively; P < 0.0001),
similar to DF. An elevation of CAT activity by 17.3% and
20.4%, and AOA by 54.2% and 41.2% (P < 0.001), was also
observed in comparison with the control AA group (Figure
3). It should be noted that the effect of both preparations
and DF on MDA, AOA, and CAT activity was similar.
3.4. Histological changes in the liver
There was no histopathological alteration of the normal
structure in hepatic parenchyma of healthy animals (data
not shown).
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The differences are statistically significant in comparison with the control AA group. + The differences are statistically significant in
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The effect of CDS and CDSM on the liver of rats with
AA was similar to the effect of DF (Table 1). Preparations
significantly diminished inflammatory infiltration of
hepatic stroma with lymphocytes by 63% (P < 0.01)
and 56.8% (P < 0.01). General inflammatory reaction
decreased by 43.4% (P < 0.05) in the CDS-treated group
and by 48.1% (P < 0.05) in the DF group in comparison
with the control AA group. CDS also markedly diminished
alteration of parenchyma by 60.2% (P < 0.02). No toxic
effects on the liver were observed after the treatment.

3.5. Effect of CDS and CDSM treatment on histological
and histochemical findings in the joints
There were no abnormalities observed in the joints of
the healthy rats (data not shown). The control CFAadministered group showed joint cartilage abrasions
and erosion, pannus formation, extensive infiltration of
inflammatory cells in the soft periarticular tissues and
synovium, edema, and angiomatosis (Table 2; Figure 4).
In the soft periarticular tissues, the preparations of CDS
and CDSM significantly reduced the general inflammatory

Table 1. Histological changes in the liver of rats with adjuvant arthritis treated with preparations CDS and CDSM.
Index

1 gr.
AA + CDS

2 gr.
AA + CDSM

3 gr.
AA + DF

4 gr.
AA control

Alteration of parenchyma

0.35 ± 0.11*

0.70 ± 0.17

0.65 ± 0.11

0.88 ± 0.16

Lymphocytes

0.30 ± 0.11*

0.30 ± 0.17*

0.35 ± 0.11*

0.81 ± 0.09

Macrophages

0.65 ± 0.15

0.60 ± 0.22

0.70 ± 0.18

0.88 ± 0.16

General

0.60 ± 0.14*

0.60 ± 0.22

0.55 ± 0.17*

1.06 ± 0.11

Inflammatory
infiltration of
hepatic stroma

Note: Hepatic tissue was fixed in neutral formalin solution, embedded in paraffin, and 5-µm-thick histological sections of the tissue
were stained with hematoxylin–eosin (for visualization of inflammation and inflammatory cell infiltration and necrosis of hepatocytes).
The histological assessment of changes in the liver was performed in a blinded manner by a pathologist. Each parameter was scored on a
0- to 3-point scale, where 0 means the absence of changes, 0.5 – traces of changes, 1 – minimal changes, 2 – moderate changes, 3 – heavy
changes. * The differences are significant in comparison with the control AA group.

Table 2. Histological changes in the joints after the treatment of adjuvant arthritis in rats with CDS and CDSM preparations.
Tissue

Soft
periarticular
tissues

1 gr.
AA + CDS

2 gr.
AA + CDSM

3 gr.
AA + DF

4 gr.
AA control

Leukocytes

1.25 ± 0.29

1.00 ± 0.23

0.60 ± 0.18*

1.63 ± 0.29

General

1.65 ± 0.17*

1.40 ± 0.16*

1.35 ± 0.08*

2.13 ± 0.08

Edema

1.15 ± 0.08*

0.90 ± 0.14*

0.65 ± 0.11*

2.06 ± 0.11

Angiomatosis

0.85 ± 0.13*

0.65 ± 0.11*

0.65 ± 0.08*

1.31 ± 0.13

Leukocytes

0.30 ± 0.13*

0.35 ± 0.11*

0.25 ± 0.11

1.13 ± 0.23

General

0.80 ± 0.08*

0.55 ± 0.14*

0.55 ± 0.12*

1.44 ± 0.15

Synovium villi proliferation

0.90 ± 0.12*

0.75 ± 0.08*

0.80 ± 0.08*

1.63 ± 0.12

Edema

0.50 ± 0.15*

0.55 ± 0.14*

0.25 ± 0.11*

1.31 ± 0.21

Angiomatosis

0.60 ± 0.10*

0.60 ± 0.10*

0.40 ± 0.10*

1.25 ± 0.23

Abrasion

0.75 ± 0.24

0.70 ± 0.13*

0.65 ± 0.15*

2.00 ± 0.00

Fissures

0.15 ± 0.11*

0.10 ± 0.07*

0.20 ± 0.11*

1.06 ± 0.27

0.15 ± 0.10*

0.25 ± 0.08*

0.05 ± 0.05*

1.00 ± 0.27

Index
Inflammatory
Infiltration

Inflammatory
Infiltration
Synovium

Cartilage

Alteration
Pannus

* The differences are significant in comparison with the control AA group.
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Figure 4. Histologic and histochemical appearance of the joints, original magnification 100×,
stained with H & E (A, C, E, G), toluidine blue (B, D, F, H) after treatment with CDS (A, B), CDSM
(C, D), DF (E, F), and from untreated control rats (G, H).
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infiltration by 22.5% (P < 0.05) and 34.3% (P < 0.002)
respectively, edema by 44.2% (P < 0.001) and 56.3% (P <
0.001), and angiomatosis by 35.1% (P < 0.05) and 50.4%
(P < 0.002) as compared with the control AA group.
Significantly lower periarticular tissue γ-metachromasia
was observed after the treatment with CDS (0.25 ± 0.08,
CDS; 0.94 ± 0.26, control; P < 0.05).
The highest pathological changes in the synovium were
found in the control untreated AA group. CDS markedly
suppressed synovium villi proliferation by 44.8% (P <
0.001) and CDSM by 54% (P < 0.001). Both CDS and
CDSM administration diminished edema (by 61.8% and
58%; P < 0.01), inflammatory infiltration with leukocytes
(by 73.5% and 69%; P < 0.01), general inflammatory
reaction (by 44.4%, P < 0.002 and 61.8%, P < 0.001), and
angiomatosis (by 52%; P < 0.02–0.001) compared with
the control AA group (Table 2). Synovium inflammatory
infiltration with macrophages was markedly lower (by
66.7%) in the CDSM-treated group (0.25 ± 0.08, CDSM;
0.75 ± 0.09, control; P < 0.001).
Both preparations significantly diminished fibrillations
(abrasions) (P < 0.001–0.0001) and fissures (P < 0.01) in
the joint cartilage, as well as pannus formation (P < 0.05),
compared with the control AA group (Figure 4).
4. Discussion
Because current treatments for arthritis result in unwanted
side effects and tend to be expensive, natural products
devoid of such disadvantages offer a novel opportunity.
The main task of this study was to confirm the idea that
better pharmacological antiinflammatory response can
be achieved by using a mixture of herbal extracts, the
mechanism of action of which is different from that of
diclofenac, an ordinary NSAID and a powerful inhibitor of
COX-2 and prostaglandin synthase activities. It is known
that the use of NSAIDs is constrained by the presence of
gastrointestinal side effects, which can be prevented by the
use of herbal preparations, such as curcumin, which is able
to prevent and treat gastric ulcers (23).
We have demonstrated the antiarthritic ability of
the preparations CDS and CDSM in AA. It was found
that they may have a significant effect on slowing AA
progression and this effect was similar to the therapeutic
effect of diclofenac (DF). Inhibition of joint swelling was
associated with marked decrease in histological changes
in the joint tissues. The main pathological changes of RA
are that leukocytes infiltrate into articular cavities and
cause recurrent synovitis (24), and that invasive pannus
causes damage to cartilage, bone, and surrounding tissue.
As observed in our study, CDS and CDSM compounds
significantly decreased synovium infiltration by leukocytes,
the general inflammatory reaction in periarticular tissues
and synovium, pannus formation, and fibrillations and
fissures in the cartilage.
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This is not surprising, because the ingredients of the
analyzed preparations are dry extracts from turmeric
(Curcuma longa), Harpagophytum procumbens (Hp), milk
thistle (Silybum marianum), and MSM. These extracts are
widely used for their beneficial effects against inflammation
and arthritis. The protection of joints after the use of these
extracts with various antioxidant, antiinflammatory,
immunomodulatory, antiproliferative effects are widely
described (12–15,17,18).
Multiple therapeutic activities of curcumin are
associated with its antiinflammatory and antioxidant
effects (12,13). Hp is widely recommended as a popular
antiinflammatory and analgesic preparation for
musculoskeletal disorders (16,25), and silymarin for its
antioxidant, antiinflammatory, antiproliferative, and
immunomodulatory effects (18). MSM also possesses
antioxidant, antiinflammatory, and antiapoptotic effects
(9,10,26).
Hence, the antiarthritic potential of the investigated
CDS and CDSM preparations is a result of their ingredients,
which show antiinflammatory activity mediated through
inhibition of different molecules involved in inflammation
including NF-kB, COX-2, 5-LOX, TNF-a, IL-1b, IL-6,
matrix metalloproteinases (MMPs), and nitric oxide (12–
15,23,27).
No particular behavior or clinical or physiological signs
were observed in the animals treated with either compound,
suggesting that the doses used of the preparations are
probably not toxic in vivo. It was confirmed by histological
examination of the liver, where lower alterations in hepatic
parenchyma and stroma were found in the treated groups.
Cytokine IL-17, a major product of T cells, which
plays an important role as an upstream mediator of RA
pathogenesis, and promotes inflammation via enhancing
the production of IL-1β, TNF-α, and IL-6 (28,29),
significantly increased in rats with AA compared to the
healthy controls in our study. In response to treatment
with CDS, its level significantly decreased. The CDSM
preparation showed a tendency to reduce this cytokine
level compared with the control AA group.
Increase in leukocyte count has been suggested to be one
of the characteristic diagnoses of arthritis. In the present
study, arthritic animals showed raised leukocyte level.
The preparations CDS and CDSM significantly decreased
leukocytes, revealing their beneficial role against arthritis.
ESR, which markedly increased in the arthritic control
group, was significantly lower after treatment with both
preparations and the standard drug DF, demonstrating
the significant benefit of the preparations in arthritic
conditions.
Antioxidant enzymes that are present in biological
systems can protect the tissue from oxidative injury. Our
results demonstrate that the activity of CAT and AOA
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was diminished in AA animals, which may have been due
to increased production of free radicals. The decrease in
antioxidant enzyme activity correlated with increased lipid
peroxidation quantified by measurement of the MDA. It
is well known that MDA is a terminal product of lipid
peroxidation, and so the content of MDA can be used to
estimate the extent of lipid peroxidation (30).
Our data of biochemical assessments showed
significantly lower levels of MDA and higher AOA and
CAT activity in the treated groups compared with the
control AA group.
Data on therapeutic effects of CDS and CDSM led
us to assay the ability of these preparations to prevent
development of AA in rats. These findings are consistent
with those reported by other authors, who have
demonstrated the ability of the extracts that composed
our preparations to reduce inflammation and to enhance

antioxidant activity, as well as induction of direct
scavenging of free radicals (9,10,12,16,18,25,26).
In conclusion, the data of this study demonstrated
that the compounds CDS and CDSM could play a role in
protecting against clinical, biochemical, immunological,
and histological alterations in rats with AA. The therapeutic
benefit was comparable with the effect achieved by treating
with the clinically available drug DF. We suggest that the
antiarthritic effect of the investigated compounds occurs
through the inhibition of oxidative stress in AA, and
increased antioxidant activity. These findings suggest that
the investigated compounds may be promising agents
for prevention and treatment of autoimmune diseases, in
combination with other drugs.
The obtained results can be used in further research
of safer arthritis treatments to avoid side effects caused by
standard therapy.
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